Artificial intelligence (AI) is rapidly transforming the healthcare landscape—and pharmacy is no exception. This course explores emerging and potential uses of AI in pharmacy practice, including workflow automation, drug information access, and tools that support patient care and clinical decision-making. You will gain insight into practical considerations, limitations, and ethical responsibilities pharmacists must navigate as AI becomes more integrated into practice.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Timothy Aungst, PharmD
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences

GET CE FOR THIS LISTENING!
The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit.
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify current and potential uses of AI that support pharmacist-led patient care services.
2. Describe considerations, limitations, and ethical concerns related to implementing AI tools in pharmacy practice.

Rachel Maynard and Timothy Aungst have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-060-H04-P
Initial release date: 3/23/2026
Expiration date: 3/23/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Sarah Grady, PharmD, BCPS, BCPP
Professor of Pharmacy Practice, Clinical Pharmacist
Drake University/Broadlawns Medical Center

GET CE FOR THIS LISTENING!
The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.

PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit.
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.
2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.

Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-059-H01-P
Initial release date: 3/16/2026
Expiration date: 3/16/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Christine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP
Professor, Pharmacy Practice and Clinical Pharmacist
Midwestern University


GET CE FOR THIS LISTENING!
The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.


PRACTICE RESOURCE
Receive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit.
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.
2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.

0.1 CEU/1.0 Hr
UAN: 0107-0000-26-081-H01-P
Initial release date: 3/9/2026
Expiration date: 3/9/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram